Q-omics provides the consensus-scored NPHP3-ACAD11 profile across patient tissues and cancer cell-line models. NPHP3-ACAD11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPHP3-ACAD11 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, NPHP3-ACAD11 RNA expression shows 16,996 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where NPHP3-ACAD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPHP3-ACAD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPHP3-ACAD11 survival associations across molecular data types. NPHP3-ACAD11 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPHP3-ACAD11 RNA expression–survival associations across cancer types. High NPHP3-ACAD11 expression shows unfavorable associations in KIRC, ACC, STAD and COAD, but favorable associations in READ and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for NPHP3-ACAD11 RNA expression.
This table summarizes NPHP3-ACAD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPHP3-ACAD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPHP3-ACAD11 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, HNSC, BLCA and LUSC. The KIRC box plot shows higher NPHP3-ACAD11 RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p < 0.001).
This table shows molecular features associated with NPHP3-ACAD11 in patient tissues and cancer cell lines. In patient samples, NPHP3-ACAD11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPHP3-ACAD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
